Alabama Society of Health-System Pharmacists
62nd Annual Clinical Meeting 
October 16 & 17, 2013
The Wynfrey Hotel, Hoover, AL 

Contact

When

Where

Registration Fees:

2 Day Pharmacist Registration
Member: $160.00
*Non-Member: $ 235.00

1 Day Pharmacist Registration:
Members: $100
*Non-Members: $175
(*Includes 1 Year Membership Fee) 

Residents: $ 52.50

Technicians: $ 25.75

Students: $ 25.75

If you are a pharmacist or pharmacy technician, ALSHP invites you to attend our Annual Clinical Meeting. This program is a knowledge and application based educational program designed for pharmacists and technicians to acquire factual knowledge. Registration fees are listed in this brochure for members and non-members. 

The Alabama Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. 6 contact hours are being offered for pharmacists, and 3 hours for pharmacy technicians. For completion of CE credit, participants must sign the sign-in sheets for each program attended, must attend the entirety of each program, and complete the online evlauation form.

Disclosure policy: It is the policy of ALSHP to ensure balance, independence, objectivity and scientific rigor in all its sponsored or jointly sponsored educational programs. All speakers participating in these programs are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s), including any corporate sponsorship of speakers. All members of the Educational Planning Committee and Board of Directors also disclose no financial interest(s) or conflict(s) of interesting in the planning of this educational conference.

Technician Program & Objectives:

THURSDAY, OCTOBER 16

3:45-4:45pm
Evolving Strategies for Stroke Prevention
in Patients with Atril Fibrillation
0468-0000-14-002-L01-T (0.1 CEUs)
Michael Bortorff, PharmD, FCCP, FNLA, CLS

At the conclusion of this Knowledge Based activity, the participant will be able to:
1. Identify the medications used for anticoagulation therapy, 2.Outline strategies to improve adherence in patients receiving anticoagulation therapy and improve treatment team coordination

FRIDAY, OCTOBER 17, 8:00am - 10:00am

8:00 am
Legislative Update
0172-0000-14-018-L03-T (0.1 CEUs)
Cara Leos, PharmD, BCPS-AQ
Tim Martin, PharmD 

At the conclusion of this Knowledge Based activity, the participant will be able to:
1. Explain State Board of Pharmacy initiatives and processes, 2. Discuss current State Board of Pharmacy Issues, 3. Describe the current legislative issues at the local, state, and national levels pertinent to all aspects of pharmacy practice including but not limited to community/retail, health system/hospital, and consultant pharmacist

9:00 am
New Drug Update
Terri Wensel, PharmD
Associate Professor of Pharmacy Practice, Samford University
McWhorter School of Pharmacy

At the conclusion of this Knowledge Based activity, the participant will be able to:
1. Define the class and basic mechanism for select new medications, 2. State special storage and dosage form consideration for select new medications, 3. State pertinent drug-drug interactions, 4. Recognize medication safety issues associated with select new medications

Pharmacist Program Objectives:

Pharmacogenetics
0172-0000-14-016-L01-P
At the conclusion of this Application Based activity, the participant will be able to:
1.  Differentiate between the types of pharmacogenomic tests available, 2.  Choose pharmacogenomic testing, most appropriate for patient populations, 3.  Interpret pharmacogenomic results to provide therapeutic reccomendations

 Evolving Strategies for Stroke Prevention in Patients with Atril Fibrillation
0000-0000-00-000-000-0
At the conclusion of this Application Based activity, the participant will be able to:
1.  Examine the importance of evidence-based treatment to mitigate the risk of stroke and other complications, 2.  Effectively assimilate knowledge of key stakeholders and NVAF/stroke treatment settings into everyday clinical practice, 3.  Compare and contrat effective treatment options for managing patients and improving outcomes in patients with NVAF, 4.  Implement strategies to improve adherence in patients receiving anticoagulation therapy and improve treatment team coordination

Patient Safety
0172-0000-14-017-L05-P
At the conclusion of this Application Based activity, the participant will be able to:
1. Outline medication errors are a significant cause of injury and why preventing medical error is the first priority of the pharmacy professional, 2. Evaulate  how system breakdowns could create medication errors and present issues with patient safety, 3. Analyze what human factors could contribute and impact medication safety, 4. Assess how error reporting is used in the clinical setting, 5. Examine what technological improvements can be made to avoid medication errors, 6. Give an example of a decision support tool that is used in the clinical setting and how it can improve safety

Legislative Update
0172-0000-14-018-L03-P
At the conclusion of this Knowledge Based activity, the participant will be able to:
1.  Explan State Board of Pharmacy initiatives and processes, 2.  Discuss current State Board of Pharmacy issues, 3.  Describe the current legislatvie issues at the local, state, and National levels pertinent to all aspects of pharmacy practice incluing but not limited to community/retail, health system/hospital, and consultant pharmacists                        

Transitions of Care
0172-0000-14-019-L04-P
At the conclusion of this Application Based activity, the participant will be able to:
1. Discuss 30 day re-hospitalization rates and the associated mortality and morbidity risks, 2. Illustrate the role of transitions of care programs in reducing the rates of 30 day re-hospitalization rates, 3. Assess the pharmacists' role in a transition of care program, 4. Examine outcomes of a pharmacist-based in home patient assessment program

he 340B Drug Discount Program:  A Review of the Basics, Consideration of Current Challenges and Opportunities, and Some "Hot Topics" in the Forefront
0172-0000-14-020-L03-P
At the conclusion of this Knowledge Based activity, the participant will be able to:
1.  Review the basic requirements for 340B  program participation and compliance, 2.  Discuss current challenges faced by facilities participating in the 340B program, 3.  Evaluate the opportunity of partnering with community oncologists to provide hospital-based infusion services, 4.  Describe the 340B "Hot Topic" of maintaining program compliance, 5.  Explain the "Hot Topics" presented at the 2014 340B Coalition in Washington, D.C.

Update on Alabama Board of Pharmacy 797/795 Inspections
0172-0000-14-021-L03-P
At the conclusion of this Knowledge Based activity, the participant will be able to:
1. Review standards and inspection criteria by which the Board of Pharmacy is reviewing institutional pharmacies, 2. Describe USP 797 and USP 795 criteria as they apply to institutional settings, 3. Identify the impact federal regulations 503a and 503b have on institutional pharmacy, 4. List the most common issues identified by the Board of Pharmacy during inspections, 5. Recognize new initiatives and practices which should be of concern to institutional pharmacies

Transitioning Inpatient to Outpatient with Home Infusion
0172-0000-14-022-L04-P
At the conclusion of this Application Based activity, the participant will be able to:
1. Explain which patients are appropriate to transition from the inpatient setting to outpatient care, 2.  Examine patient and/or third party benefits available to allow patients to receive outpatient treatment, 3.  Assess the requirements for coordination of care, initial education and ongoing monitoring, 4.  Discuss significance of appropriate discharge planning

Home Use of Inotropic Therapy for Heart Failure Patients
0172-0000-14-023-L01-P
At the conclusion of this Application Based activity, the participant will be able to:
1.  Describe the indications for parenteral cardiac inotropes which include congestive heart failure and cardiac decompensation, 2.  List the parenteral cardiac inotropic therapies used in the home setting, 3.  Explain the advantages of home parenteral cardiac inotropic therapy, 4.  Illustrate how a home infusion pharmacy must document the medical necessity for parenteral cardia inotropic therapy for a patient with heart failure